Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drugs With Better Sales Have Better Development Times, Study Finds

Executive Summary

Drugs with strong sales were developed more quickly than drugs with weaker sales, according to an analysis published in the March/April issue of Health Affairs

You may also be interested in...



Lilly Aims To Lower NME Cost To $800 Mil. Via Incremental Improvements

Lilly is aiming for a 33% reduction in the cost of launching a new molecular entity by 2010 through incremental improvements in several stages of the drug developmental process

Lilly Aims To Lower NME Cost To $800 Mil. Via Incremental Improvements

Lilly is aiming for a 33% reduction in the cost of launching a new molecular entity by 2010 through incremental improvements in several stages of the drug developmental process

Key To First-Cycle Approval Is To Meet Early And Often, Consultants Tell FDA

An independent analysis of FDA's first-cycle review performance provides support for the agency's request for additional funding for pre-submission meetings

UsernamePublicRestriction

Register

PS046955

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel